Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial
Open accessAbstract
Importance: Cefepime and piperacillin-tazobactam are commonly administered to hospitalized adults for empirical treatment of infection. Although piperacillin-tazobactam has been hypothesized to cause acute kidney injury and cefepime has been hypothesized to cause neurological dysfunction, their comparative safety has not been evaluated in a randomized clinical trial. Objective: To determine whether the choice between cefepime and piperacillin-tazobactam affects the risks of acute kidney injury or neurological dysfunction. Design, Setting, and Participants: The Antibiotic Choice on Renal Outcomes (ACORN) randomized clinical trial compared cefepime vs piperacillin-tazobactam in adults for whom a clinician initiated an order for antipseudomonal antibiotics within 12 hours of presentation to the hospital in the emergency department or medical intensive care unit at an academic medical center in the US between November 10, 2021, and October 7, 2022. The final date of follow-up was November 4, 2022. Interventions: Patients were randomized in a 1:1 ratio to cefepime or piperacillin-tazobactam. Main Outcomes and Measures: The primary outcome was the highest stage of acute kidney injury or death by day 14, measured on a 5-level ordinal scale ranging from no acute kidney injury to death. The 2 secondary outcomes were the incidence of major adverse kidney events at day 14 and the number of days alive and free of delirium and coma within 14 days. Results: There were 2511 patients included in the primary analysis (median age, 58 years [IQR, 43-69 years]; 42.7% were female; 16.3% were Non-Hispanic Black; 5.4% were Hispanic; 94.7% were enrolled in the emergency department; and 77.2% were receiving vancomycin at enrollment). The highest stage of acute kidney injury or death was not significantly different between the cefepime group and the piperacillin-tazobactam group; there were 85 patients (n = 1214; 7.0%) in the cefepime group with stage 3 acute kidney injury and 92 (7.6%) who died vs 97 patients (n = 1297; 7.5%) in the piperacillin-tazobactam group with stage 3 acute kidney injury and 78 (6.0%) who died (odds ratio, 0.95 [95% CI, 0.80 to 1.13], P = .56). The incidence of major adverse kidney events at day 14 did not differ between groups (124 patients [10.2%] in the cefepime group vs 114 patients [8.8%] in the piperacillin-tazobactam group; absolute difference, 1.4% [95% CI, −1.0% to 3.8%]). Patients in the cefepime group experienced fewer days alive and free of delirium and coma within 14 days (mean [SD], 11.9 [4.6] days vs 12.2 [4.3] days in the piperacillin-tazobactam group; odds ratio, 0.79 [95% CI, 0.65 to 0.95]). Conclusions and Relevance: Among hospitalized adults in this randomized clinical trial, treatment with piperacillin-tazobactam did not increase the incidence of acute kidney injury or death. Treatment with cefepime resulted in more neurological dysfunction. Trial Registration: ClinicalTrials.gov Identifier: NCT05094154
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Randomized and observational evidence has focused attention on renal outcomes during broad beta-lactam and vancomycin-containing therapy.
“Randomized and observational evidence has focused attention on renal outcomes during broad beta-lactam and vancomycin-containing therapy (22, 23).”
From Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis (2026) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250 · see citing works
Self-citationASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215 · see citing works
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082 · see citing works
Self-citation(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326 · see citing works
Family history of subarachnoid haemorrhage: supplemental value of scrutinizing all relatives.
Greebe, P., Bromberg, J. E. C., Rinkel, G. J. E., Algra, A., & van Gijn, J. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.273 · Cited by 4,137 · see citing works
Seymour, C. W., Liu, V. X., Iwashyna, T. J., Brunkhorst, F. M., Rea, T. D., Scherag, A., Rubenfeld, G., Kahn, J. M., Shankar-Hari, M., Singer, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0288 · Cited by 3,939 · see citing works
Sessler, C. N., Gosnell, M. S., Grap, M. J., Brophy, G. M., O'Neal, P. V., Keane, K. A., Tesoro, E. P., & Elswick, R. K. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2107138 · Cited by 3,695 · see citing works
Ely, E. W., Inouye, S. K., Bernard, G. R., Gordon, S., Francis, J., May, L., Truman, B., Speroff, T., Gautam, S., Margolin, R., et al. (2001) · JAMA · doi:10.1001/jama.286.21.2703 · Cited by 3,210 · see citing works
Self-citationPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294 · see citing works
Balanced crystalloids versus saline in critically ill adults.
Semler, M. W., Self, W. H., Wanderer, J. P., Ehrenfeld, J. M., Wang, L., Byrne, D. W., Stollings, J. L., Kumar, A. B., Hughes, C. G., Hernandez, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711584 · Cited by 1,433 · see citing works
Self-citationBalanced Crystalloids versus Saline in Noncritically Ill Adults
Self, W. H., Semler, M. W., Wanderer, J. P., Wang, L., Byrne, D. W., Collins, S. P., Slovis, C. M., Lindsell, C. J., Ehrenfeld, J. M., Siew, E. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711586 · Cited by 1,156 · see citing works
Self-citationSchandelmaier, S., Briel, M., Varadhan, R., Schmid, C. H., Devasenapathy, N., Hayward, R. A., Gagnier, J., Borenstein, M., van der Heijden, G. J. M. G., Dahabreh, I. J., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.200077 · Cited by 749 · see citing works
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness
Girard, T. D., Exline, M. C., Carson, S. S., Hough, C. L., Rock, P., Gong, M. N., Douglas, I. S., Malhotra, A., Owens, R. L., Feinstein, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808217 · Cited by 576 · see citing works
Self-citationCefepime-induced neurotoxicity: a systematic review
Payne, L. E., Gagnon, D. J., Riker, R. R., Seder, D. B., Glisic, E. K., Morris, J. G., & Fraser, G. L. (2017) · Critical Care · doi:10.1186/s13054-017-1856-1 · Cited by 347 · see citing works
Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock
Leligdowicz, A., Dodek, P., Norena, M., Wong, H., Kumar, A., & Kumar, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1875oc · Cited by 279 · see citing works
Tong, S. Y. C., Lye, D. C., Yahav, D., Sud, A., Robinson, J. O., Nelson, J., Archuleta, S., Roberts, M. A., Cass, A., Paterson, D. L., et al. (2020) · JAMA · doi:10.1001/jama.2020.0103 · Cited by 279 · see citing works
Evidence for the involvement of GABAA receptor blockade in convulsions induced by cephalosporins
Sugimoto, M., Uchida, I., Mashimo, T., et al. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00188-6 · Cited by 194 · see citing works
Design of Clinical Trials in Acute Kidney Injury
Palevsky, P. M., Molitoris, B. A., Okusa, M. D., Levin, A., Waikar, S. S., Wald, R., Chertow, G. M., Murray, P. T., Parikh, C. R., Shaw, A., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12791211 · Cited by 175 · see citing works
Haloperidol for the Treatment of Delirium in ICU Patients
Andersen‐Ranberg, N. C., Poulsen, L. M., Perner, A., Wetterslev, J., Estrup, S., Hästbacka, J., Morgan, M. P. G., Citerio, G., Caballero, J., Lange, T., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2211868 · Cited by 174 · see citing works
Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study
Boschung-Pasquier, L., Atkinson, A., Kastner, L. K., Banholzer, S., Haschke, M., Buetti, N., Furrer, D. I., Hauser, C., Jent, P., Que, Y., et al. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.06.028 · Cited by 147 · see citing works
Characterizing Cefepime Neurotoxicity: A Systematic Review
Appa, A. A., Jain, R., Rakita, R. M., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx170 · Cited by 109 · see citing works
Miano, T. A., Hennessy, S., Yang, W. P., Dunn, T. G., Weisman, A. R., Oniyide, O., Agyekum, R. S., Turner, A. P., Ittner, C. A. G., Anderson, B. J., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06811-0 · Cited by 98 · see citing works
Colantuoni, E., Scharfstein, D. O., Wang, C., Hashem, M. D., Leroux, A., Needham, D. M., & Girard, T. D. (2018) · BMJ · doi:10.1136/bmj.j5748 · Cited by 90 · see citing works
Identification of Major Adverse Kidney Events Within the Electronic Health Record
Semler, M. W., Rice, T. W., Shaw, A., Siew, E. D., Self, W. H., Kumar, A. B., Byrne, D. W., Ehrenfeld, J. M., & Wanderer, J. P. (2016) · Journal of Medical Systems · doi:10.1007/s10916-016-0528-z · Cited by 86 · see citing works
Self-citationBellos, I., Karageorgiou, V., Pergialiotis, V., & Perrea, D. N. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.019 · Cited by 79 · see citing works
Blevins, A., Lashinsky, J. N., McCammon, C., Kollef, M. H., Micek, S. T., & Juang, P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02658-18 · Cited by 76 · see citing works
Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports
Durand-Maugard, C., Lemaire‐Hurtel, A., Gras‐Champel, V., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks012 · Cited by 66 · see citing works
OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam
Wen, S., Wang, C., Duan, Y., et al. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.037 · Cited by 62 · see citing works
Reversible Coma Secondary to Cefepime Neurotoxicity
Abanades, S., Nolla, J., Rodríguez-Campello, A., et al. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d322 · Cited by 56 · see citing works
Li, H., Lee, C., Wu, T., et al. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00682-y · Cited by 54 · see citing works
Pais, G. M., Liu, J., Avedissian, S. N., Hiner, D., Xanthos, T. T., Chalkias, A. F., d’Aloja, E., Locci, E., Gilchrist, A., Prozialeck, W. C., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz563 · Cited by 52 · see citing works
Cefepime-induced neurotoxicity
Lee, S. (2019) · Journal of Neurocritical Care · doi:10.18700/jnc.190109 · Cited by 33 · see citing works
Chang, J. H. T., Pais, G. M., Valdez, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02132-21 · Cited by 31 · see citing works
The safety of cefepime in the treatment of infection
Drago, L., & Vecchi, E. D. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.4.377 · Cited by 24 · see citing works
O'Callaghan, K., Hay, K. E., Lavana, J. D., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106010 · Cited by 24 · see citing works
Novel clinical trial designs for the development of new antiretroviral agents
Mani, N., Murray, J. S., Gulick, R. M., et al. (2012) · AIDS · doi:10.1097/qad.0b013e3283519371 · Cited by 16 · see citing works
Balderia, P. G., Chandorkar, A., Kim, Y., et al. (2015) · Journal of Patient Safety · doi:10.1097/pts.0000000000000225 · Cited by 13 · see citing works
Qian, E. T., Wang, L., Stollings, J. L., et al. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231184177 · Cited by 5 · see citing works
Self-citationQian, E. T., Casey, J. D., Wright, A. T., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066995 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117 · see citing works
Zhang, Y., Liao, G., Song, J., Liao, Y., & Zhang, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1924203
- Authors
- Qian, E. T., Casey, J. D., Wright, A., Wang, L., Shotwell, M. S., Siemann, J. K., Dear, M. L., Stollings, J. L., Lloyd, B. D., Marvi, T. K., Seitz, K. P., Nelson, G. E., Wright, P. W., Siew, E. D., Dennis, B. M., Wrenn, J. O., Andereck, J. W., Han, J. H., Self, W. H., Semler, M. W., Rice, T. W., Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group, Bernard, G. R., Dittus, R. S., Dwyer, S., Embi, P. J., Freundlich, R. E., Gatto, C. L., Harrell, F. E., Harris, P. A., Hartert, T., Hayman, J., Ivory, C. H., Kleinpell, R., Kripalani, S., Lindsell, C. J., Liska, L. A., Luther, P., Morrison, J., Nantais, T., Pulley, J. M., Rehm, K., Rice, T. W., Rotheman, R. L., Runyan, P., Self, W. H., Semler, M. W., Steaban, R., Stone, C. A., Walker, P. D., Wilkens, C. H., Wright, A., Zukerman, A. D., Fitzgerald, C., Casey, J. D., Seitz, K. P., Rhoads, J., Womack, K., Wang, L., Imhoff, B., & Shotwell, M. S.
- Affiliations
- Vanderbilt University Medical Center (US)
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- VA Tennessee Valley Healthcare System (US)
- Vanderbilt University (US)
- for the Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group
- Corresponding author
- Qian, Edward T.
- ORCID
- Qian, Edward T.
- Siemann, Justin K.
- Dear, Mary Lynn
- Stollings, Joanna L.
- Marvi, Tanya K.
- Nelson, George E.
- Siew, Edward D.
- Dennis, Bradley M.
- Wrenn, Jesse O.
- Andereck, Jonathan W.
- Han, Jin H.
- Bernard, Gordon R
- Freundlich, Robert E
- Gatto, Cheryl L
- Harrell, Frank E
- Harris, Paul A
- Hartert, Tina
- Ivory, Catherine H
- Kleinpell, Ruth
- Kripalani, Sunil
- Lindsell, Christopher J
- Morrison, Jay
- Pulley, Jill M
- Stone, Cosby A
- Walker, Philip D
- Rhoads, Jillian
- Womack, Kelsey
- Imhoff, Brant
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-10-24
- Volume
- 330
- Issue
- 16
- Pages
- 1557
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC10576861
- OpenAlex
- W4387638731
- Cited by
- 150
- References
- 39
- Citations by year
- 2026: 55 · 2025: 43 · 2024: 50 · 2023: 2
- FWCI
- 28.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (U24TR001608, UL1TR002243, U24TR004437)
- Agency for Healthcare Research and Quality (R18HS026158, R18 HS025910, R18 HS026616)
- National Heart, Lung, and Blood Institute (OT2HL156812, K23HL153584, K23HL143053, T32HL087738, R33HL155810, U01HL168478, R01HL161635, R01HL164909)
- National Institute of General Medical Sciences (R35GM145375)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK114809)
- National Center for Research Resources (UL1RR024975)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
- Keywords
- cefepime, piperacillin-tazobactam, acute kidney injury, neurological disorders, delirium, coma, empirical antibiotic therapy, hospitalized adults, antibiotic safety, renal outcomes, mortality, vancomycin, emergency department, intensive care unit, sepsis, critically ill patients
- MeSH terms
- Cefepime, Piperacillin, Tazobactam Drug Combination, Adult, Anti-Bacterial Agents, Coma, Delirium, Drug Therapy, Combination, Female, Humans, Kidney, Male, Middle Aged, Piperacillin, Retrospective Studies, Sepsis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
